PMD Company Profile

A Blowout results, by Marker Therapeutics Inc over the fourth quarter of 2022 earnings season

For the financial fourth quarter of 2022 Marker Therapeutics Inc decreased a loss per share of $-0.05 per share compare to $-0.12 a year before and earnings per share improved from $-0.08 per share from the preceding reporting period.

Sales advanced sharply by 166.499 % to $3.31 millions from $1.24 millions in the similar reporting period a year before and sequentially Sales fell by -16.215 % from $3.95 millions.

Bluerock Homes Trust Inc reported that Sales have improved significantly, all along the most recent fiscal period

BHM announced very solid Sales elevation of 1950.962 % year on year to $25.47 millions in the most recent fiscal period, but increased a shortfall per share at $-0.48.

As one of many corporations, the MTAC disclosed as well its fourth quarter of 2022 results

Trailing the big players in the Blank Checks sector, some lesser known corporations are reporting the numbers. MTAC mentioned it has booked operating loss of $-1.35582 millions, for the fourth quarter of 2022.

For the fiscal third quarter of 2022 company Deficit has expanded of $-8.78 per share compare to $0.17 a year ago and Income per Share improved from $-6,194.86 per share from the previous reporting season.

Sales remained unscathed to $0.00 millions from $0.32 millions in the similar reporting season a year ago and sequentially Sales doubled from $0.00 millions.

The company reported operating shortfall of $-8.144 millions, in the fourth quarter of 2022

The stockholders have not anticipated any changes at the top-line during the the earnings season of the October to December 31 2022 period at the company. However, investors pay very near attention to ATOSs' operating shortfall that came in at $-8.144 millions, in the same period.